These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238 [TBL] [Abstract][Full Text] [Related]
3. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479 [TBL] [Abstract][Full Text] [Related]
4. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763 [TBL] [Abstract][Full Text] [Related]
5. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Chin TW; Parry RL; Donahoe PK Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529 [TBL] [Abstract][Full Text] [Related]
6. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Ragin RC; Donahoe PK; Kenneally MK; Ahmad MF; MacLaughlin DT Protein Expr Purif; 1992 Jun; 3(3):236-45. PubMed ID: 1392620 [TBL] [Abstract][Full Text] [Related]
7. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385 [TBL] [Abstract][Full Text] [Related]
8. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990 [TBL] [Abstract][Full Text] [Related]
13. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants. Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786 [TBL] [Abstract][Full Text] [Related]
15. [Antagonistic actions of testosterone and the anti-mullerian hormone on the mullerian duct of the chick embryo in culture in vitro]. Weniger JP; Zeis A Arch Anat Microsc Morphol Exp; 1982; 71(2):99-106. PubMed ID: 6897160 [TBL] [Abstract][Full Text] [Related]
16. Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids. Kuroda T; Lee MM; Ragin RC; Hirobe S; Donahoe PK Endocrinology; 1991 Dec; 129(6):2985-92. PubMed ID: 1954882 [TBL] [Abstract][Full Text] [Related]